ProstaScint

ProstaScint®

Capromab pendetide, see there.
References in periodicals archive ?
has released interim results from a Phase 2 clinical trial of IAB2M, the company's proprietary imaging agent for management of prostate cancer, demonstrating superior performance in detecting disease compared with ProstaScint and conventional imaging technologies including CT scans, MRI scans and bone scans.
A copy of the full prescribing information for CAPHOSOL, QUADRAMET, PROSTASCINT and SOLTAMOX, including Boxed Warnings, warnings, precautions, adverse events and other safety information may be obtained in the U.
PROSTASCINT is the first and only commercial monoclonal antibody-based agent that targets prostate-specific membrane antigen (PSMA) to image the extent and spread of prostate cancer.
On May 20, 2015 Aytu entered into an agreement with Jazz Pharmaceuticals to acquire ProstaScint, an imaging agent used to detect the extent and spread of prostate cancer that is marketed in the U.
QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer, and SOLTAMOX is the first liquid hormonal therapy approved in the U.
The study evaluated patients whose PROSTASCINT images showed a localization pattern known as central abdomen uptake (CAU), a finding suggestive of metastatic disease, as compared to those without such findings.
Sales of PROSTASCINT kits, the first and only commercial monoclonal antibody-based agent that targets prostate-specific membrane antigen (PSMA) to image the extent and spread of prostate cancer, increased to $2.
To date, Cytogen's 2007 research and development expenses have been comprised of costs associated with its three proprietary radiopharmaceuticals, QUADRAMET, PROSTASCINT, and CYT-500.
7 million in the same period of 2005, and reflects QUADRAMET and PROSTASCINT manufacturing costs, sales-based royalties paid by Cytogen, and the amortization of the up-front payments to acquire the marketing rights to QUADRAMET and SOLTAMOX.
In particular, Cytogen's business is subject to a number of significant risks, which include, but are not limited to the risk of obtaining the necessary regulatory approvals for new QUADRAMET or PROSTASCINT indications, as well as other factors expressed from time to time in Cytogen's periodic filings with the Securities and Exchange Commission (the "SEC").
New technologies reported at Society of Nuclear Medicine annual meeting aimed to pace the future of PROSTASCINT imaging, data suggest use of advanced image processing tools could significantly shorten acquisition times without compromising image quality
i) The study evaluated the outcomes of patients whose PROSTASCINT images showed uptake in the central abdomen, a finding suggestive of metastatic disease, as compared to those without such findings.